

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

PE/Cyanine7 anti-mouse/human CD11b

RRID:AB_312799

Type: Antibody

Proper Citation

BioLegend Cat# 101216, RRID:AB_312799

Antibody Information

URL: http://antibodyregistry.org/AB_312799

Proper Citation: BioLegend Cat# 101216, RRID:AB_312799

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_312799

Vendor: BioLegend

Catalog Number: 101216

Alternative Catalog Numbers: 101215

Record Creation Time: 20250820T033338+0000

Record Last Update: 20250820T163430+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse/human CD11b.

No alerts have been found for PE/Cyanine7 anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 138 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. *Cell reports. Medicine*, 102532.

Khan F, et al. (2026) Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis. *Cancer research*, 86(1), 12.

Li L, et al. (2025) A bladder-blood immune barrier constituted by suburothelial perivascular macrophages restrains uropathogen dissemination. *Immunity*, 58(3), 568.

Tang Q, et al. (2025) Gut bacterial L-lysine alters metabolism and histone methylation to drive dendritic cell tolerance. *Cell reports*, 44(1), 115125.

Luka? N, et al. (2025) Midline 1 associated with Fas signaling enhances murine antigen-induced arthritis. *Frontiers in cell and developmental biology*, 13, 1451093.

Pan S, et al. (2025) Decoding the ontogeny of myeloid lineage diversity by cross-species and developmental analyses of hematopoietic progenitor atlases. *Cell reports*, 44(3), 115406.

Wu X, et al. (2025) Cathepsin C-driven enhancement of neutrophil extracellular trap formation contributes to acute lung injury. *iScience*, 28(12), 113928.

Bastos J, et al. (2025) Monocytes can efficiently replace all brain macrophages and fetal liver monocytes can generate bona fide SALL1+ microglia. *Immunity*, 58(5), 1269.

Leesang TE, et al. (2025) Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation. *Cell reports*, 44(10), 116379.

Song Q, et al. (2025) *Bifidobacterium animalis* suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid. *Cell reports*, 44(8), 116132.

Ciccone MF, et al. (2025) Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors. *Nature communications*, 16(1), 9168.

Haacke N, et al. (2025) Innate immune training of osteoclastogenesis promotes inflammatory bone loss in mice. *Developmental cell*, 60(13), 1854.

Mix MR, et al. (2025) Repetitive antigen stimulation in the periphery dictates the composition and recall responses of brain-resident memory CD8⁺ T cells. *Cell reports*, 44(2), 115247.

Zhang Q, et al. (2025) Intravascular immune surveillance against viremia requires spatiotemporal coordination between Kupffer cells and ILC1s. *Cell reports*, 44(11), 116488.

Chen D, et al. (2025) DNASE1L3-expressing dendritic cells promote CD8⁺ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. *Cancer cell*, 43(9), 1758.

Peng F, et al. (2025) Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions. *Cancer cell*.

Wu J, et al. (2025) Targeting mitochondrial complex I of CD177⁺ neutrophils alleviates lung ischemia-reperfusion injury. *Cell reports. Medicine*, 6(5), 102140.

Hu J, et al. (2025) CD169⁺ macrophages identify and eliminate tumor cells in colorectal cancer through CD169/CD43 interaction and FasL-driven apoptosis. *Cell reports*, 44(10), 116351.

Wang S, et al. (2025) ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy. *Cell reports. Medicine*, 6(9), 102336.

Arnouk SM, et al. (2025) Depleting IL1R2⁺ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 Immunotherapy. *Cancer research*, 85(23), 4681.